Efficacy and safety of the 589/1319 nm solid-state dual-wavelength laser combined with topical benzoyl peroxide for inflammatory acne vulgaris: a split-face randomized controlled trial
| dc.contributor.author | Boonpethkaew S. | |
| dc.contributor.author | Ratanapokasatit Y. | |
| dc.contributor.author | Chirasuthat S. | |
| dc.contributor.author | Wattanakrai P. | |
| dc.contributor.correspondence | Boonpethkaew S. | |
| dc.contributor.other | Mahidol University | |
| dc.date.accessioned | 2025-04-03T18:06:46Z | |
| dc.date.available | 2025-04-03T18:06:46Z | |
| dc.date.issued | 2025-12-01 | |
| dc.description.abstract | The 589/1319 nm solid-state dual-wavelength (SSDW) laser, which does not require consumable dye, has the potential to target inflammation and sebum production in acne vulgaris pathogenesis. To assess the efficacy and safety of 598/1319 nm SSDW laser as an adjunctive treatment to conventional treatment, 18 patients with bilateral facial acne, with inflammatory papules or pustules, were recruited. Patients were instructed to apply 2.5% benozoyl peroxide (BPO), the drug for inflammatory acne, to their entire face throughout the study. One side of the face was randomly assigned to receive 4 sessions of 589/1319 nm SSDW laser treatments, administered every 2 weeks. After the last laser treatment, 3 monthly follow-ups were scheduled. Inflammatory lesion count (ILC) and acne-related skin parameters, including hemoglobin level, melanin level, skin depression, and skin roughness were measured. Adverse events (AEs) and patients’ satisfaction were assessed. At the 3-month follow-up, the ILC reduced by 46% on the adjunctive laser (BPO + laser) side (p = 0.0080), compared with a 29% reduction on the BPO monotherapy side (p = 0.1875). On the adjunctive laser side, the change in ILC positively correlated with the change in melanin level (r = 0.51, p = 0.0301) and showed a trend towards a positive correlation with the change in depression volume (r = 0.45, p = 0.0606) and roughness level (r = 0.42, p = 0.0806). The patients reported a pain score of 3.4 ± 2.3 on scale of 10. No serious AEs occurred. Patients’ satisfaction scores were higher with the adjunctive laser therapy, although this was not statistically significant (p = 0.2758). In conclusion, the 589/1319 nm SSDW laser provided a synergistic effect as an adjunctive treatment to BPO in inflammatory acne in terms of reducing ILC and improving post inflammatory hyperpigmentation without causing discomfort or downtime. | |
| dc.identifier.citation | Archives of Dermatological Research Vol.317 No.1 (2025) | |
| dc.identifier.doi | 10.1007/s00403-025-04146-6 | |
| dc.identifier.eissn | 1432069X | |
| dc.identifier.issn | 03403696 | |
| dc.identifier.scopus | 2-s2.0-105001154253 | |
| dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/123456789/109303 | |
| dc.rights.holder | SCOPUS | |
| dc.subject | Medicine | |
| dc.title | Efficacy and safety of the 589/1319 nm solid-state dual-wavelength laser combined with topical benzoyl peroxide for inflammatory acne vulgaris: a split-face randomized controlled trial | |
| dc.type | Article | |
| mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105001154253&origin=inward | |
| oaire.citation.issue | 1 | |
| oaire.citation.title | Archives of Dermatological Research | |
| oaire.citation.volume | 317 | |
| oairecerif.author.affiliation | Ramathibodi Hospital |
